COVID19VIGIE-COVIDNCT04699851
Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens
A study testing Tailored recommendations and General recommendation in people with COVID19 and Tailored Recommendations, run by Laval University at 1 site in Canada.
Trial summary
People with chronic diseases including atherosclerotic heart disease, high blood pressure and diabetes are considered as a group with a high vulnerability. The COVID-19 pandemic ranging the world is rendering these people with chronic diseases even more vulnerable as they are subjected to a higher risk of COVID-19… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID19, Tailored Recommendations, Citizen Self-reported Symptoms
- What is being tested?
- Tailored recommendations and General recommendation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,200 participants
- Where
- 1 siteCanada
- Study dates
- 18 Nov 2020to 18 May 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 18 years old
- Living in Canada
- Able to give an informed consent
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
Laval University
Québec, g1v0a6
Jean-Sébastien Paquette, MD MSc, 450-759-3060, jean-sebastien.paquette@fmed.ulaval.ca
About this study
People with chronic diseases including atherosclerotic heart disease, high blood pressure and diabetes are considered as a group with a high vulnerability. The COVID-19 pandemic ranging the world is rendering these people with chronic diseases even more vulnerable as they are subjected to a higher risk of COVID-19 related complications. General recommendations issued by the public health departments (PHD) do not take into consideration the personal situation of every citizen and therefore do not provide a personalized guidance to people with high vulnerability. The investigators hypothesis is that if participants receive adapted and personalized public health recommendations, they will be more adherent to the recommendations issued by the PHD and have better health outcomes than those who receive only general recommendations.
In the current trial, the investigators propose to co-develop a web-based portal (Vigie-COVID) that provides tailored recommendations based on the situation of each participant and adapted to the COVID-19 status, the behavior risk associated to contamination, the risk of complications and the health risks related to confinement. Using a cohort of people aged 18 and over in the province of Quebec, this randomized clinical trial will use a nested a double-blind experimental design where the tailored recommendations will be compared to the general recommendations of the PHD. The expected results from this trial include: 1) Improvement in the rate of compliance with the PHD recommendations in the group receiving the tailored recommendations; 2) Improvement of the quality and the quantity of the COVID 19 epidemiological data available for population health research in the Quebec region; 3) Decrease in the load in clinics (self-diagnosis); 4) Improving the state of health of individuals. The portal will be co-constructed in collaboration between various key players (citizens, patient partners, clinicians, researchers, companies, managers, decision-makers and representatives of the PHD) and aims to allow the recommendations of the PHD to be tailored according to the specific situation of each citizen-user in order to promote preventive behavior in times of pandemic. Overall, the ultimate goal is to obtain a global epidemiological portrait in order to identify the determinants and indicators of sustainable health and their impacts. After the pandemic, this might enable the implementation of a personalized monitoring of chronic diseases.
Read the detailed description
The COVID-19 pandemic is raging in the world, including Quebec. As of May 22, 2020, more than 46,141 cases have been identified in Quebec, including 3,865 deaths. The virus causes heterogeneous clinical manifestations. People may be asymptomatic, have mild to moderate symptoms (cough, fever, myalgia), or a severe form requiring hospitalization and transfer to intensive care units. In a small proportion of people, it can cause death. Health emergency status was declared in Quebec on March 13, 2020 to allow the deployment of the measures suggested by the Public Health Department (PHD). Different types of recommendations (general, targeted, personalized and tailored) are available to optimize the prevention and management of COVID-19. General interventions are aimed at the entire population (eg: washing hands, keeping 2 meters apart). Targeted interventions target a vulnerable population (eg: patients with diabetes, the elderly, etc.). Personalized interventions are addressed specifically to a person, without necessarily being adapted to that person (eg: a general letter addressed to an individual by his name written in the header). The appropriate intervention considers the individual's reality (eg medical, environmental). Tailored interventions require a capacity for dynamic analysis and evaluation of information but are generally more effective in changing behavior (3). This evaluation also allows sorting of relevant information. Indeed, during a pandemic, a citizen may have a perception of contradictory information or be overloaded with information from different media. The tailored assessment allows citizens to have a clearer message in their reality. As mentioned above, in the case of COVID-19, the heterogeneity of symptom presentation implies different realities for each individual. In a potentially large proportion of cases, people may be asymptomatic or have mild to moderate flu-like symptoms. Thus, many infected people will not consult in the health network. It has been estimated that there are 10 times more people infected than those who are screened. Establishing a diagnosis of infected people is a key factor in ensuring a coherent epidemiological watch at the PHD. It is an indicator to monitor deconfinement and predict the second wave. COVID-19 infection is therefore a reportable disease. Moreover, diagnosing the disease in individuals with low symptoms makes them aware of their risk of transmission, as well as that of their contacts, so that they can adapt their behavior to the recommendations of the PHD. In addition, medical monitoring is critical in some vulnerable people with COVID-19. In fact, people aged 70 and / or suffering from certain chronic diseases (such as high blood pressure, atherosclerotic heart disease, obesity and diabetes) are at greater risk of developing the severe form of the disease. Citizens seem less inclined to consult their doctors during this period of disruption in the network. The preventive recommendations for these people, whether or not they have COVID-19, must be absolutely tailored in order to provide health care. Stricter preventive containment measures can have a negative impact on functional capacity or the risk of co-morbidities in this population due to changes in healthy lifestyle habits. Providing recommendations tailored to their situation on these habits (eg physical activity, healthy eating, sleep) could help reduce these negative effects.
In order to improve the health and safety of the population, the investigators propose to co-develop, with citizens, patient partners, clinicians, companies, managers, decision-makers and representatives of the PHD, a citizen portal in order to produce appropriate recommendations related to the COVID-19 status (positive or negative), the risk of complications (severity of symptoms and medical history), the risk of contamination (environmental prevalence of the disease) and the risks related to confinement. This portal will be adapted to level 2 literacy and validated by usability tests. From questionnaires self-administered to citizens, the tool will allow dynamic monitoring of symptoms related to COVID-19, collaborate with the PHD to improve the epidemiological portrait of the situation by identifying people who do not consult in the health system network and to bridge the gap with their family doctor.
Objectives: 1) Evaluate the feasibility of an efficient collaborative system between the PHD, citizens, patients and health professionals allowing the optimization of appropriate recommendations in both prevention and detection during the COVID-19 pandemic; 2) Produce recommendations concerning preventive behaviors related to COVID-19 tailored to the medical and environmental reality of each citizen; 3) Compare the proportion of users complying with the recommendations between those receiving tailored recommendations and those receiving general recommendations; 4) Observe the evolution of the state of health of individuals in real time by collecting socio-demographic, psychosocial and physiological data, including symptoms related to COVID-19, and data from measures surrounding confinement to the using a self-administered assessment tool.
Methodology:
Specification: This is a clinical intervention study of a cohort including a nested and randomized double-blind experimental design, where the tailored recommendations will be compared to the general recommendations. Population and sample: People aged 18 and over, residing in the Quebec City area, will be solicited according to an advertising strategy and different collaborations which will enable the access to a cohort of 1407 participants (as of May 22, 2020).
Programming: This project will be designed in three parts. The first component consists of co-developing a citizen portal including a secure database hosted on the PULSAR platform to record the information of each participant including their current state of health (chronic diseases, COVID-19 status, symptoms), their geographic location (postal code or dissemination area) and their psycho-social situation. The second part consists of using the information from the first part and analyzing them using a decision-making algorithm to propose recommendations tailored to the reality of each person which will be dynamically updated according to the evolution of the pandemic and the person's state of health. A measurement will take place after 3 weeks of the procedure.
Statistical Analysis Plan: This analysis plan was developed in collaboration with biostatisticians and epidemiologists from the VITAM Research Center. Being in the context of a 1: 1 randomized trial with an intervention group and a control group, the investigators calculated the number of individuals with a threshold of statistical significance of 5%. According to DiMatteo et al., adherence to medical recommendations is 50% to 75% in the general population. In order to be conservative, the investigators therefore assumed a 50% membership ratio for the control group (general recommendations). The working hypothesis is that individuals receiving adapted recommendations will adhere to the recommendations more than those in the control group. Based on the above formula, the minimum required number of people for each group varies with the effect size (the minimum difference to be able to detect). In order to detect a minimum intergroup difference of effect of 10% (if any) in the proportion of individuals complying with the recommendations, 514 individuals per group will be needed. Descriptive analyzes will be performed to describe the sample. For continuous quantitative variables, measures of central tendencies will be obtained and for categorical variables, absolute and relative frequencies will be reported. The rate of compliance with recommendations by intervention group as well as the prevalence of COVID19 status and reportable disease will be calculated. The investigators will then proceed to a temporal analysis by profile enumeration: the start of each time interval will be marked each time a change in recommendation occurs. Given the exploratory nature of these analyzes the primary outcome will be dichotomized (participants who follow the recommendations versus the others). The difference in proportions will be calculated by time interval and then a Cochrane-Armitage test will be done to test the time trend of compliance with the recommendations in each of the intervention groups. All statistical analyzes will be performed using SAS software version 9.4.
Recruitment: An existing portal, developed with patients over the past 2 years, will be adapted for the purposes of the project (PULSAR). Collaboration with an already existent public health project, the MAVIPAN project, will allow the recruitment of participants who have already agreed to be contacted for other projects. The MAVIPAN questionnaire already contains several socio-demographic information and on the physical and psychological health of the participants. The other questions will be adapted from existing tools (clinical diagnostic criteria for COVID-19, MADO, electronic questionnaires from the INSPQ, iCARE questionnaire). All data will be hosted on PULSAR, a collaborative platform for research and intervention in sustainable health, ensuring data security. A partnership with the PHD will make it possible to harmonize collection tools according to national and international standards to facilitate data collection and analysis.
Timeline: The platform will be launched in November 2020. Recruitment and data collection in the context of the project will take place until April 2021.
Expected results and impact:
Primary: Improvement in the rate of compliance with the PHD recommendations based on the iCARE study. Measurement of the number of exits and contacts (e.g .: vulnerable person going out (danger for them) or positive COVID-19 person going out (danger for others), going to a doctor vs staying at home, doing their own grocery shopping vs having it delivered, going to work or staying at home, going out for sports (running, walking).
Secondary: 1. COVID-19 status (new cases diagnosed); improved data collected in the population (Public Health); reduction in the burden in clinics (self-diagnosis) 2. Patient health status: assessed by self-reported health questionnaires already integrated into the PULSAR platform (Chronic disease; socio-demographic data; sleep; lifestyle habits; quality of life; physiological data; negative effects linked to confinement and social distancing (e.g. loss of functional capacity, negative impact on healthy lifestyles); related to recommendations for vulnerable populations. The tailored recommendations will allow citizens to receive precise information related to their medical condition and their environment, to better understand the measures and to comply more closely with them. Being in the period of deconfinement, reducing risky behavior can reduce the transmission and spread of COVID-19. The data will be useful to front-line clinicians to optimize the management of COVID-19 by having recommendations tailored to the medical condition of their patients. The PHD will benefit from a more realistic portrait of the prevalence of symptoms related to COVID-19 and optimize the use of its resources. In addition, this data will make it possible to make recommendations related to reducing the risks associated with confinement for vulnerable populations. The Vigie-COVID portal will remain after the pandemic to monitor epidemics but can also be used to monitor vulnerable populations with chronic diseases. The link that unites citizens, the PHD and health professionals will last, given the added value for the health network.
- Being tested
- Tailored recommendations, General recommendation
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored recommendationsBehavioural
Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
General recommendationBehavioural
The control group will receive general recommendations by email about health prevention in a pandemic.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey. Receives: Behavioral: Tailored recommendations |
| Control | Active comparator | The control group will receive general recommendations about health prevention in a pandemic. Receives: Behavioral: General recommendation |
What is being measured
The primary outcome is the main question the study is designed to answer.
improvement in mask wearing behavior
The measure will be the frequency of mask wearing when the participant is in a situation where it is recommended by public health to wear the mask
Measured: 3 months
improvement in social distancing behavior
The measure will be the frequency of social distancing (2 meters or more) when the participant is in a situation where it is recommended by public health.
Measured: 3 months
improvement in hand washing behavior
The measure will be the frequency of hand washing when the participant is in a situation where it is recommended by public health.
Measured: 3 months
improvement in daily fruit consumption
the measure will be the portion of fruit and vegetables consumed per day
Measured: 3 months
improvement in the amount of daily sleep hours
The measure will be the amount of hour of sleep by day
Measured: 3 months
improvement in the amount of weekly minutes of exercise
The measure will be the amount of minutes of moderate to intense exercise by week
Measured: 3 months
Secondary outcomes (3)
Platform participation
The amount of total inscription of participants
Measured: 3 months
Platform sustainability short term
the number of participants who respond to the survey 3 weeks after the start of the survey
Measured: 3 weeks
Platform sustainability long term
the number of participants who respond to the survey 3 months after the start of the survey
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2021
- Study start18 Nov 2020
- Primary completion18 Apr 2021 (estimated)
- Study completion18 May 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for COVID19Studies of the same condition, open and under way.
- More trials run by Laval UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The project has 2 arms. The intervention arm are participant who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey. The control group will receive general recommendations about health prevention in a pandemic.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Laval University
- Sponsor type
- University, hospital or other
- Collaborators
- Réseau-1 Québec, Réseau de recherche en santé des populations du Québec
- Responsible party
- Principal investigator, Jean-Sébastien Paquette, Laval University
- Investigators
- Jean-Sébastien Paquette, Principal investigator, Laval University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04699851
- Sponsor's protocol ID
- vigie-covid
- Acronym
- VIGIE-COVID
- Status last verified
- Jan 2021
- First submitted
- 25 Nov 2020
- Last updated
- 8 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: PULSAR santé durable platform
Publications
Lustria ML, Noar SM, Cortese J, Van Stee SK, Glueckauf RL, Lee J. A meta-analysis of web-delivered tailored health behavior change interventions. J Health Commun. 2013;18(9):1039-69. doi: 10.1080/10810730.2013.768727. Epub 2013 Jun 10.
PubMed 23750972Williams SN, Armitage CJ, Tampe T, Dienes K. Public perceptions and experiences of social distancing and social isolation during the COVID-19 pandemic: a UK-based focus group study. BMJ Open. 2020 Jul 20;10(7):e039334. doi: 10.1136/bmjopen-2020-039334.
PubMed 32690752Islam AKMN, Laato S, Talukder S, Sutinen E. Misinformation sharing and social media fatigue during COVID-19: An affordance and cognitive load perspective. Technol Forecast Soc Change. 2020 Oct;159:120201. doi: 10.1016/j.techfore.2020.120201. Epub 2020 Jul 12.
PubMed 32834137Chow EJ, Schwartz NG, Tobolowsky FA, Zacks RLT, Huntington-Frazier M, Reddy SC, Rao AK. Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington. JAMA. 2020 May 26;323(20):2087-2089. doi: 10.1001/jama.2020.6637.
PubMed 32301962Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, Getaz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 Aug 1;396(10247):313-319. doi: 10.1016/S0140-6736(20)31304-0. Epub 2020 Jun 11.
PubMed 32534626Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing Y, Guo H, Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.
PubMed 32335169Ammar A, Brach M, Trabelsi K, Chtourou H, Boukhris O, Masmoudi L, Bouaziz B, Bentlage E, How D, Ahmed M, Muller P, Muller N, Aloui A, Hammouda O, Paineiras-Domingos LL, Braakman-Jansen A, Wrede C, Bastoni S, Pernambuco CS, Mataruna L, Taheri M, Irandoust K, Khacharem A, Bragazzi NL, Chamari K, Glenn JM, Bott NT, Gargouri F, Chaari L, Batatia H, Ali GM, Abdelkarim O, Jarraya M, Abed KE, Souissi N, Van Gemert-Pijnen L, Riemann BL, Riemann L, Moalla W, Gomez-Raja J, Epstein M, Sanderman R, Schulz SV, Jerg A, Al-Horani R, Mansi T, Jmail M, Barbosa F, Ferreira-Santos F, Simunic B, Pisot R, Gaggioli A, Bailey SJ, Steinacker JM, Driss T, Hoekelmann A. Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey. Nutrients. 2020 May 28;12(6):1583. doi: 10.3390/nu12061583.
PubMed 32481594Altena E, Baglioni C, Espie CA, Ellis J, Gavriloff D, Holzinger B, Schlarb A, Frase L, Jernelov S, Riemann D. Dealing with sleep problems during home confinement due to the COVID-19 outbreak: Practical recommendations from a task force of the European CBT-I Academy. J Sleep Res. 2020 Aug;29(4):e13052. doi: 10.1111/jsr.13052. Epub 2020 May 4.
PubMed 32246787Jimenez-Pavon D, Carbonell-Baeza A, Lavie CJ. Physical exercise as therapy to fight against the mental and physical consequences of COVID-19 quarantine: Special focus in older people. Prog Cardiovasc Dis. 2020 May-Jun;63(3):386-388. doi: 10.1016/j.pcad.2020.03.009. Epub 2020 Mar 24. No abstract available.
PubMed 32220590DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004 Mar;42(3):200-9. doi: 10.1097/01.mlr.0000114908.90348.f9.
PubMed 15076819
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens
- ClinicalTrials.gov ID
- NCT04699851
- Acronym / sponsor ID
- VIGIE-COVID / vigie-covid
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Laval UniversityUniversity, hospital or other
- Collaborators
- Réseau-1 Québec, Réseau de recherche en santé des populations du Québec
- Study start
- 18 Nov 2020 (actual)
- Primary completion
- 18 Apr 2021 (estimated)
- Study completion
- 18 May 2021 (estimated)
- First posted
- 7 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People with chronic diseases including atherosclerotic heart disease, high blood pressure and diabetes are considered as a group with a high vulnerability. The COVID-19 pandemic ranging the world is rendering these people with chronic diseases even more vulnerable as they are subjected to a higher risk of COVID-19 related complications. General recommendations issued by the public health departments (PHD) do not take into consideration the personal situation of every citizen and therefore do not provide a personalized guidance to people with high vulnerability. The investigators hypothesis is that if participants receive adapted and personalized public health recommendations, they will be more adherent to the recommendations issued by the PHD and have better health outcomes than those who receive only general recommendations.
In the current trial, the investigators propose to co-develop a web-based portal (Vigie-COVID) that provides tailored recommendations based on the situation of each participant and adapted to the COVID-19 status, the behavior risk associated to contamination, the risk of complications and the health risks related to confinement. Using a cohort of people aged 18 and over in the province of Quebec, this randomized clinical trial will use a nested a double-blind experimental design where the tailored recommendations will be compared to the general recommendations of the PHD. The expected results from this trial include: 1) Improvement in the rate of compliance with the PHD recommendations in the group receiving the tailored recommendations; 2) Improvement of the quality and the quantity of the COVID 19 epidemiological data available for population health research in the Quebec region; 3) Decrease in the load in clinics (self-diagnosis); 4) Improving the state of health of individuals. The portal will be co-constructed in collaboration between various key players (citizens, patient partners, clinicians, researchers, companies, managers, decision-makers and representatives of the PHD) and aims to allow the recommendations of the PHD to be tailored according to the specific situation of each citizen-user in order to promote preventive behavior in times of pandemic. Overall, the ultimate goal is to obtain a global epidemiological portrait in order to identify the determinants and indicators of sustainable health and their impacts. After the pandemic, this might enable the implementation of a personalized monitoring of chronic diseases.
Detailed description
The COVID-19 pandemic is raging in the world, including Quebec. As of May 22, 2020, more than 46,141 cases have been identified in Quebec, including 3,865 deaths. The virus causes heterogeneous clinical manifestations. People may be asymptomatic, have mild to moderate symptoms (cough, fever, myalgia), or a severe form requiring hospitalization and transfer to intensive care units. In a small proportion of people, it can cause death. Health emergency status was declared in Quebec on March 13, 2020 to allow the deployment of the measures suggested by the Public Health Department (PHD). Different types of recommendations (general, targeted, personalized and tailored) are available to optimize the prevention and management of COVID-19. General interventions are aimed at the entire population (eg: washing hands, keeping 2 meters apart). Targeted interventions target a vulnerable population (eg: patients with diabetes, the elderly, etc.). Personalized interventions are addressed specifically to a person, without necessarily being adapted to that person (eg: a general letter addressed to an individual by his name written in the header). The appropriate intervention considers the individual's reality (eg medical, environmental). Tailored interventions require a capacity for dynamic analysis and evaluation of information but are generally more effective in changing behavior (3). This evaluation also allows sorting of relevant information. Indeed, during a pandemic, a citizen may have a perception of contradictory information or be overloaded with information from different media. The tailored assessment allows citizens to have a clearer message in their reality. As mentioned above, in the case of COVID-19, the heterogeneity of symptom presentation implies different realities for each individual. In a potentially large proportion of cases, people may be asymptomatic or have mild to moderate flu-like symptoms. Thus, many infected people will not consult in the health network. It has been estimated that there are 10 times more people infected than those who are screened. Establishing a diagnosis of infected people is a key factor in ensuring a coherent epidemiological watch at the PHD. It is an indicator to monitor deconfinement and predict the second wave. COVID-19 infection is therefore a reportable disease. Moreover, diagnosing the disease in individuals with low symptoms makes them aware of their risk of transmission, as well as that of their contacts, so that they can adapt their behavior to the recommendations of the PHD. In addition, medical monitoring is critical in some vulnerable people with COVID-19. In fact, people aged 70 and / or suffering from certain chronic diseases (such as high blood pressure, atherosclerotic heart disease, obesity and diabetes) are at greater risk of developing the severe form of the disease. Citizens seem less inclined to consult their doctors during this period of disruption in the network. The preventive recommendations for these people, whether or not they have COVID-19, must be absolutely tailored in order to provide health care. Stricter preventive containment measures can have a negative impact on functional capacity or the risk of co-morbidities in this population due to changes in healthy lifestyle habits. Providing recommendations tailored to their situation on these habits (eg physical activity, healthy eating, sleep) could help reduce these negative effects.
In order to improve the health and safety of the population, the investigators propose to co-develop, with citizens, patient partners, clinicians, companies, managers, decision-makers and representatives of the PHD, a citizen portal in order to produce appropriate recommendations related to the COVID-19 status (positive or negative), the risk of complications (severity of symptoms and medical history), the risk of contamination (environmental prevalence of the disease) and the risks related to confinement. This portal will be adapted to level 2 literacy and validated by usability tests. From questionnaires self-administered to citizens, the tool will allow dynamic monitoring of symptoms related to COVID-19, collaborate with the PHD to improve the epidemiological portrait of the situation by identifying people who do not consult in the health system network and to bridge the gap with their family doctor.
Objectives: 1) Evaluate the feasibility of an efficient collaborative system between the PHD, citizens, patients and health professionals allowing the optimization of appropriate recommendations in both prevention and detection during the COVID-19 pandemic; 2) Produce recommendations concerning preventive behaviors related to COVID-19 tailored to the medical and environmental reality of each citizen; 3) Compare the proportion of users complying with the recommendations between those receiving tailored recommendations and those receiving general recommendations; 4) Observe the evolution of the state of health of individuals in real time by collecting socio-demographic, psychosocial and physiological data, including symptoms related to COVID-19, and data from measures surrounding confinement to the using a self-administered assessment tool.
Methodology:
Specification: This is a clinical intervention study of a cohort including a nested and randomized double-blind experimental design, where the tailored recommendations will be compared to the general recommendations. Population and sample: People aged 18 and over, residing in the Quebec City area, will be solicited according to an advertising strategy and different collaborations which will enable the access to a cohort of 1407 participants (as of May 22, 2020).
Programming: This project will be designed in three parts. The first component consists of co-developing a citizen portal including a secure database hosted on the PULSAR platform to record the information of each participant including their current state of health (chronic diseases, COVID-19 status, symptoms), their geographic location (postal code or dissemination area) and their psycho-social situation. The second part consists of using the information from the first part and analyzing them using a decision-making algorithm to propose recommendations tailored to the reality of each person which will be dynamically updated according to the evolution of the pandemic and the person's state of health. A measurement will take place after 3 weeks of the procedure.
Statistical Analysis Plan: This analysis plan was developed in collaboration with biostatisticians and epidemiologists from the VITAM Research Center. Being in the context of a 1: 1 randomized trial with an intervention group and a control group, the investigators calculated the number of individuals with a threshold of statistical significance of 5%. According to DiMatteo et al., adherence to medical recommendations is 50% to 75% in the general population. In order to be conservative, the investigators therefore assumed a 50% membership ratio for the control group (general recommendations). The working hypothesis is that individuals receiving adapted recommendations will adhere to the recommendations more than those in the control group. Based on the above formula, the minimum required number of people for each group varies with the effect size (the minimum difference to be able to detect). In order to detect a minimum intergroup difference of effect of 10% (if any) in the proportion of individuals complying with the recommendations, 514 individuals per group will be needed. Descriptive analyzes will be performed to describe the sample. For continuous quantitative variables, measures of central tendencies will be obtained and for categorical variables, absolute and relative frequencies will be reported. The rate of compliance with recommendations by intervention group as well as the prevalence of COVID19 status and reportable disease will be calculated. The investigators will then proceed to a temporal analysis by profile enumeration: the start of each time interval will be marked each time a change in recommendation occurs. Given the exploratory nature of these analyzes the primary outcome will be dichotomized (participants who follow the recommendations versus the others). The difference in proportions will be calculated by time interval and then a Cochrane-Armitage test will be done to test the time trend of compliance with the recommendations in each of the intervention groups. All statistical analyzes will be performed using SAS software version 9.4.
Recruitment: An existing portal, developed with patients over the past 2 years, will be adapted for the purposes of the project (PULSAR). Collaboration with an already existent public health project, the MAVIPAN project, will allow the recruitment of participants who have already agreed to be contacted for other projects. The MAVIPAN questionnaire already contains several socio-demographic information and on the physical and psychological health of the participants. The other questions will be adapted from existing tools (clinical diagnostic criteria for COVID-19, MADO, electronic questionnaires from the INSPQ, iCARE questionnaire). All data will be hosted on PULSAR, a collaborative platform for research and intervention in sustainable health, ensuring data security. A partnership with the PHD will make it possible to harmonize collection tools according to national and international standards to facilitate data collection and analysis.
Timeline: The platform will be launched in November 2020. Recruitment and data collection in the context of the project will take place until April 2021.
Expected results and impact:
Primary: Improvement in the rate of compliance with the PHD recommendations based on the iCARE study. Measurement of the number of exits and contacts (e.g .: vulnerable person going out (danger for them) or positive COVID-19 person going out (danger for others), going to a doctor vs staying at home, doing their own grocery shopping vs having it delivered, going to work or staying at home, going out for sports (running, walking).
Secondary: 1. COVID-19 status (new cases diagnosed); improved data collected in the population (Public Health); reduction in the burden in clinics (self-diagnosis) 2. Patient health status: assessed by self-reported health questionnaires already integrated into the PULSAR platform (Chronic disease; socio-demographic data; sleep; lifestyle habits; quality of life; physiological data; negative effects linked to confinement and social distancing (e.g. loss of functional capacity, negative impact on healthy lifestyles); related to recommendations for vulnerable populations. The tailored recommendations will allow citizens to receive precise information related to their medical condition and their environment, to better understand the measures and to comply more closely with them. Being in the period of deconfinement, reducing risky behavior can reduce the transmission and spread of COVID-19. The data will be useful to front-line clinicians to optimize the management of COVID-19 by having recommendations tailored to the medical condition of their patients. The PHD will benefit from a more realistic portrait of the prevalence of symptoms related to COVID-19 and optimize the use of its resources. In addition, this data will make it possible to make recommendations related to reducing the risks associated with confinement for vulnerable populations. The Vigie-COVID portal will remain after the pandemic to monitor epidemics but can also be used to monitor vulnerable populations with chronic diseases. The link that unites citizens, the PHD and health professionals will last, given the added value for the health network.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- The project has 2 arms. The intervention arm are participant who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey. The control group will receive general recommendations about health prevention in a pandemic.
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Tailored recommendationsThe intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey. |
| Control | Active comparator | Behavioral: General recommendationThe control group will receive general recommendations about health prevention in a pandemic. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 18 years old
- Living in Canada
- Able to give an informed consent
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tailored recommendationsTailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey. | Behavioural | Intervention |
| General recommendationThe control group will receive general recommendations by email about health prevention in a pandemic. | Behavioural | Control |
Primary outcome
improvement in mask wearing behavior
Time frame: 3 months
The measure will be the frequency of mask wearing when the participant is in a situation where it is recommended by public health to wear the mask
improvement in social distancing behavior
Time frame: 3 months
The measure will be the frequency of social distancing (2 meters or more) when the participant is in a situation where it is recommended by public health.
improvement in hand washing behavior
Time frame: 3 months
The measure will be the frequency of hand washing when the participant is in a situation where it is recommended by public health.
improvement in daily fruit consumption
Time frame: 3 months
the measure will be the portion of fruit and vegetables consumed per day
improvement in the amount of daily sleep hours
Time frame: 3 months
The measure will be the amount of hour of sleep by day
improvement in the amount of weekly minutes of exercise
Time frame: 3 months
The measure will be the amount of minutes of moderate to intense exercise by week
3 secondary outcomes
Platform participation
Time frame: 3 months
Platform sustainability short term
Time frame: 3 weeks
Platform sustainability long term
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2021.
- Background: PubMed 23750972Lustria ML, Noar SM, Cortese J, Van Stee SK, Glueckauf RL, Lee J. A meta-analysis of web-delivered tailored health behavior change interventions. J Health Commun. 2013;18(9):1039-69. doi: 10.1080/10810730.2013.768727. Epub 2013 Jun 10.
- Background: PubMed 32690752Williams SN, Armitage CJ, Tampe T, Dienes K. Public perceptions and experiences of social distancing and social isolation during the COVID-19 pandemic: a UK-based focus group study. BMJ Open. 2020 Jul 20;10(7):e039334. doi: 10.1136/bmjopen-2020-039334.
- Background: PubMed 32834137Islam AKMN, Laato S, Talukder S, Sutinen E. Misinformation sharing and social media fatigue during COVID-19: An affordance and cognitive load perspective. Technol Forecast Soc Change. 2020 Oct;159:120201. doi: 10.1016/j.techfore.2020.120201. Epub 2020 Jul 12.
- Background: PubMed 32301962Chow EJ, Schwartz NG, Tobolowsky FA, Zacks RLT, Huntington-Frazier M, Reddy SC, Rao AK. Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington. JAMA. 2020 May 26;323(20):2087-2089. doi: 10.1001/jama.2020.6637.
- Background: PubMed 32534626Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, Getaz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 Aug 1;396(10247):313-319. doi: 10.1016/S0140-6736(20)31304-0. Epub 2020 Jun 11.
- Background: PubMed 32335169Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing Y, Guo H, Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.
- Background: PubMed 32481594Ammar A, Brach M, Trabelsi K, Chtourou H, Boukhris O, Masmoudi L, Bouaziz B, Bentlage E, How D, Ahmed M, Muller P, Muller N, Aloui A, Hammouda O, Paineiras-Domingos LL, Braakman-Jansen A, Wrede C, Bastoni S, Pernambuco CS, Mataruna L, Taheri M, Irandoust K, Khacharem A, Bragazzi NL, Chamari K, Glenn JM, Bott NT, Gargouri F, Chaari L, Batatia H, Ali GM, Abdelkarim O, Jarraya M, Abed KE, Souissi N, Van Gemert-Pijnen L, Riemann BL, Riemann L, Moalla W, Gomez-Raja J, Epstein M, Sanderman R, Schulz SV, Jerg A, Al-Horani R, Mansi T, Jmail M, Barbosa F, Ferreira-Santos F, Simunic B, Pisot R, Gaggioli A, Bailey SJ, Steinacker JM, Driss T, Hoekelmann A. Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey. Nutrients. 2020 May 28;12(6):1583. doi: 10.3390/nu12061583.
- Background: PubMed 32246787Altena E, Baglioni C, Espie CA, Ellis J, Gavriloff D, Holzinger B, Schlarb A, Frase L, Jernelov S, Riemann D. Dealing with sleep problems during home confinement due to the COVID-19 outbreak: Practical recommendations from a task force of the European CBT-I Academy. J Sleep Res. 2020 Aug;29(4):e13052. doi: 10.1111/jsr.13052. Epub 2020 May 4.
- Background: PubMed 32220590Jimenez-Pavon D, Carbonell-Baeza A, Lavie CJ. Physical exercise as therapy to fight against the mental and physical consequences of COVID-19 quarantine: Special focus in older people. Prog Cardiovasc Dis. 2020 May-Jun;63(3):386-388. doi: 10.1016/j.pcad.2020.03.009. Epub 2020 Mar 24. No abstract available.
- Background: PubMed 15076819DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004 Mar;42(3):200-9. doi: 10.1097/01.mlr.0000114908.90348.f9.
- Main website for the project, it explain the project and links to the research platformLink provided by the sponsor.
- Données COVID-19 au Québec. Institut national de santé publique du Québec (INSPQ)Link provided by the sponsor.
- Mesures communautaires de santé publique pour atténuer la propagation des maladies à coronavirus (COVID-19) au Canada. Gouvernement du CanadaLink provided by the sponsor.
- Avis provisoire du 14 mars 2020. relatif à la prise en charge des patients à risque de forme sévère de Covid-19Link provided by the sponsor.
- Roy S, 2020. Coronavirus: l'inquiétante baisse des consultations médicales en ville. Le FigaroLink provided by the sponsor.
- Statistique Canada. Enquête internationale sur l'alphabétisation et les compétence des adultes (EIA CA) 2003Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided. PULSAR santé durable platform
Related trials for COVID19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean-Sébastien Paquette principal investigator
Laval University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tailored recommendations and General recommendation in people with COVID19 and Tailored Recommendations, run by Laval University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jean-Sébastien Paquette, MD (450-759-3060, jean-sebastien.paquette@fmed.ulaval.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
improvement in mask wearing behavior (time frame: 3 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04699851, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2021.